Want to see HK:9996 full AI Analyst Report?
9996 Stock Chart & Stats
HK$6.51
-HK$0.07(-1.80%)
At close: 4:00 PM EST
HK$6.51
-HK$0.07(-1.80%)
Day’s Range― - ―
52-Week RangeHK$3.73 - HK$9.36
Previous CloseN/A
Volume6.00K
Average Volume (3M)1.88M
Market Cap
HK$2.91B
Enterprise ValueHK$2.21B
Total Cash (Recent Filing)HK$610.52M
Total Debt (Recent Filing)HK$434.22M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding674,736,940
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$897.68M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue ScalingGross margins near 67% indicate durable product-level profitability and pricing power in implantable interventional devices. Coupled with multi-year revenue expansion, this suggests scalable unit economics that can fund R&D, clinical evidence generation, and commercial buildout as volumes grow.
Conservative Balance SheetLow leverage (debt/equity ~0.24) provides financial flexibility to sustain operations and pursue regulatory or commercial milestones without immediate refinancing pressure. Manageable capitalization reduces short- to medium-term solvency risk while the company works toward profitability.
Growing Revenue & Focused Product MixMid-teens revenue growth and a concentrated portfolio in TAVR and neurovascular therapy areas support durable demand from procedure volume and consumable sales. A focused device franchise can drive recurring accessory/consumable revenue and create a long-term commercial runway as adoption expands.
Bears Say
Persistent UnprofitabilityOperating losses and a roughly -29% net margin show the business has not yet achieved profitable scale. Continued unprofitability limits self-funding for growth, depresses returns to equity holders, and makes long-term strategy contingent on converting margins positive or securing ongoing external capital.
Weak Cash GenerationMaterial negative free cash flow (~-325M) and negative operating cash flow increase reliance on external financing. Persistent cash burn raises dilution and refinancing risk, and can constrain investment in sales, clinical trials, or manufacturing capacity needed to capture market opportunities over the next several quarters.
Negative Returns On CapitalROE around -11% indicates the company is destroying shareholder capital rather than creating it. Sustained negative returns can erode equity value, reduce investor appetite, and pressure management to either accelerate profitability or pursue financing strategies that may dilute existing holders.
Peijia Medical Ltd. News
9996 FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was HK$3.73 and its highest was HK$9.36 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is HK$2.91B.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 57 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.218 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.218.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Overvalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 674,736,940 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -HK$0.218 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.792%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in HK:9996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---